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ABSTRACT 
This study was conducted for qualitative analysis of serum proteins separated by SDS-PAGE and stained by 
Coomassie Brilliant Blue R-250 in order to describe the preliminary identification of serum proteins that may act as 
diagnostic marker in benign prostatic hyperplasia. Serum samples of 23 biopsy confirmed cases of benign prostatic 
hyperplasia and normal controls of similar age group were subjected to SDS-PAGE on a 12% resolving gel, followed by 
staining with Coomassie Brilliant Blue R-250. Protein fractions were analyzed using computer software program 
“GeneGenius Gel Documentation and Analysis System”. Major protein fractions ranging in molecular weights from 1.45-
157 kDa were observed. Raw volumes of most of the protein fractions seem to be increased in majority of benign prostatic 
hyperplasia cases as compared to normal control. Protein fractions 55-57 kDa were undetected in normal controls under 80 
years of age but appeared in 56% of benign prostatic hyperplasia cases. Two dimensional gel electrophoresis and silver 
staining of these samples could yield better resolution of protein fraction 55-57 kDa that could serve as marker for benign 
prostatic hyperplasia.  
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INTRODUCTION 
Benign prostatic hyperplasia (BPH) has been 
variably defined as prostate enlargement, histologic 
hyperplasia, lower urinary tract symptoms, diminished 
uroflow or urodynamic measurements or it has been 
viewed as an indication for prostatic surgery. The prostate 
gets larger in most men as they get older, and overall, 45% 
of men over the age of 46 can expect to suffer from the 
symptoms of BPH if they survive 30 years [1]. Incidence 
rates increase from 3 cases per 1000 man-years at age 45-
49 years, to 38 cases per 1000 man-years by the age of 75-
79 years. Whereas the prevalence rate is 2.7% for men 
aged 45-49, it increases to 24% by the age of 80 years [1]. 
Increase in age and an intact androgen supply seem to be 
prerequisites for BPH development. Apart from that, no 
other risk factors have been identified uncontrovertibly 
[2]. The incidence of BPH is far higher than prostate 
cancer that causes the greatest number of cancer deaths in 
American
 males [3]. 
The PSA serum test has contributed to earlier
 
detection, however, 65-75% of moderately elevated PSA
 
levels are attributed to BPH, often resulting in unnecessary
 
biopsies [4]. Several approaches have been undertaken to 
improve
 the PSA test such as measuring PSA velocity [5], 
PSA density [6], and assessing ratios between free, 
complexed and total
  PSA serum values with various 
degrees of success [7]. Combinations
 of markers such as 
free PSA, IGF-I, and IGF-binding protein
 3 have resulted 
in improved diagnostic discrimination between
 BPH and 
prostate cancer [8]. Additional improvement in early
 
detection, diagnosis, and prognosis will likely require the
 
measurement of a panel of protein biomarkers.  
Proteins initiate all cell functions and pathways, 
identifying
  differentially expressed proteins between 
normal and pathological
  state, leading to a better 
understanding of the cellular mechanisms
  involved in 
disease. Some proteins are down-regulated and others
 are 
up-regulated with the onset of disease, depending on a 
protein’s
  specific function, undergoing disease-specific 
posttranslational
 modifications [9-11]. This identification 
of changes in
 protein profile that occur during pathological 
condition could lead to the discovery of
 protein biomarkers 
and novel strategies for the improvement
 of detection and 
diagnosis of BPH without any discrimination. This will 
also minimize unnecessary biopsies.  
Sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE) is a versatile and powerful 
technique widely used for protein separation based on 
their molecular weights [12]. In this study protein fractions 
were studied by SDS-PAGE due to its importance in the 
resolution of serum proteins. In this study the aim of 
performing SDS-PAGE was to make a comparison 
between protein profiles found in healthy subjects and 
BPH cases an to identify some novel proteins that are lost 
or changed (raised or lowered) in concentrations in 
diseased subjects. 
 
MATERIALS AND METHODS 
This study was conducted at NHRC a centre of 
PMRC and Institute of Biochemistry and Biotechnology 
University of the Punjab Lahore.  
 
Inclusion criteria 
BPH subjects were selected on the basis of lower 
urinary tract symptoms (frequent urination, urgency and 
dribbling) and DRE findings, which were further, 
confirmed BPH patients on biopsy. Controls displayed 
none of these symptoms. 
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Exclusion criteria 
Patients who had undergone any surgical 
intervention of prostate were excluded. Biopsy confirmed 
prostate cancer patients were also excluded from study. 
Blood samples of 23 biopsy confirmed BPH 
patients of different ages were collected from Urology 
units of Shaikh Zayed Medical Complex and Jinnah 
Hospital Lahore. Normal healthy males matched by age 
were also included from general community as control 
group. Similarities of their basic confounding factors were 
ensured. The samples were distributed into four groups 
according to age as group I (50-59 yrs.), group II (60-69 
yrs.), group III (70-79 yrs.) and group IV (>80 yrs.). 
Group I (50-59 years) included one normal control (N1) 
and six BPH cases (B1-B6). Group II (60- 69yr.) included 
one control (N2) and six BPH cases (B7-B12). Group III 
(70-79 yrs.) had one control (N3) and five BPH cases (B13-
B17) and group IV included a control (N4) and six BPH 
cases (B18-B23). Sera were separated and stored at -80
oC 
till analysis. 
 
Reagent preparation  
 
12% resolving gel 
8mls were prepared by dissolving 30% 
acrylamide-bisacrylamide, 3.35ml of 3M Tris-HCl (pH-
8.8), 0.2ml of 10% SDS in 8.45ml of distilled water, 
followed by 4ul TEMED and 65ul of 10% ammonium 
persulfate. 
 
Stacking gel 
It was prepared by dissolving 0.9ml of 30% 
acrylamide-bisacrylamide, 55ul 10% SDS, 0.35ml of 1M 
Tris-HCl (pH 6.8) in 4.9ml distilled water followed by 
addition of 38ul bromophenol blue, 5ul TEMED and 55ul 
10% ammonium persulfate.  
 
Tris-glycine buffer  
15g of trizma base, 72g of glycine and 5g SDS 
were dissolved in distilled water and final volume was 
made up to 1000ml. The solution was 5x diluted before 
electrophoresis. 
 
Staining solution 
0.5g Coomassie Brilliant Blue R-250 were 
dissolved in 450ml methanol and then mixed with 90ml 
glacial acetic acid and 450ml distilled water. 
 
Destaining solution 
It was prepared by mixing 300ml (30%) 
methanol, 100ml (10%) acetic acid and 600ml water. 
Since equal quantities of protein from each sample under 
comparison must be loaded on to gels for electrophoretic 
analysis, so the total protein content of each serum sample 
(cases and controls) was estimated by Bradford assay 
(1976) [13]. 
In each group serum samples of control and BPH 
cases were separated by loading in their respective wells. 
The gel was then electrophoresed at constant supply of 
12mA and voltage of 150V in a minicold lab maintained at 
4
oC. The gel was stained using Coomassie Brilliant Blue 
R-250 and then destained. Protein fractions appeared as 
dark bands on a light background. Gels were photographed 
using “GeneSnap” and their images were formatted and 
analysed by using “GeneTools”, which were part of the 
computer software program “GeneGenius Gel 
Documentation and Analysis System”. The molecular 
weight of each protein fraction was determined by using 
molecular weight markers as standard. The raw volume 
was calculated by the software using band height and 
intensity, which was a measure of relative quantity of 
protein in each sample.   
 
RESULTS  
In group I (50-59 years) protein fractions ranging 
in molecular weight from 1.45-157 kDa were observed 
when samples were subjected to SDS-PAGE. Raw volume 
of most of the protein fractions in this group were 
increased in majority of BPH cases, while some proteins 
were decreased as compared to normal control (N1). In one 
sample (B5), it was observed that most of the major protein 
fractions (157, 140, 131, 122, 114, 100 and 76) were 
undetectable and remaining was decreased in raw volume 
when compared to other cases and normal control in same 
group. Furthermore raw volumes of all protein fractions 
were also down regulated in sample (B2). Protein fractions 
55-57 kDa molecular weights were also found absent in 
the control but present in two of BPH cases (B4, B6). 
(Figure-1) 
 
 
       M       N1    B1      B2      B3     B4     B5   B6 
 
Figure-1 Serum protein profile of control (N1) and cases 
(B1-B6) in group I (50-59 yr.), resolved on 12% resolving 
Gel by SDS-PAGE. 
M: Protein size markers (from top to bottom): 67, 45, 24, 
18, 13 and 1.45 kDa. 
 
In group II (60-69 years) when samples of BPH 
cases and normal control were subjected to SDS-PAGE, it 
showed same patterns as in group I. Raw volume of 
protein fractions were up regulated. Exceptional behavior 
was observed in two samples (B9 and B12), in which 
protein fractions of molecular weight 131, 122, 114 and 
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100 kDa, appearing in all the other samples were absent 
and remaining fractions were decreased in raw volumes. 
Like group I, protein fraction of 55-57 kDa was also found 
absent in control (N2), but it was seen in BPH cases i.e. B7, 
B8 and B10 of group II (Figure-2). 
 
 
M     N2     B7     B8     B9      B10     B11     B12 
 
Figure-2. Serum protein profile of control (N2) and cases 
(B7-B12) in group I (60-69 yr.), resolved on 12% resolving 
gel by SDS-PAGE. 
M: Protein size markers (from top to bottom): 67, 45, 24, 
18, 13 and 1.45 kDa. 
 
Unlike group I and II, group III (70-79 years) 
showed an overall increase in raw volume of protein 
fractions in all BPH cases (B13-B17) as compared to normal 
control (N3). Whereas similar to normal controls in group I 
and II protein fractions 55-57 kDa was absent in the 
control (N3) but appeared in B15 and B16 BPH cases in this 
group (Figure-3). 
 
In group IV (>80 years), the raw volume of most 
of the protein fractions was found to be increased in BPH 
cases relative to the control (N4). Anomalous behavior in 
this Group was displayed by one sample (B23), in which 
four protein fractions of molecular weights 131, 122, 114 
and 100 kDa were not seen. The 114 kDa fraction was also 
found absent in two samples (B18 and B22). Protein 
fractions 50-57 kDa was seen in control (N4) of this group 
which was found absent in normal controls of all other 
groups. These protein fractions were also seen in all BPH 
case (B18-B23) of this group (Figure-4). 
 
 
 
 
              M    N3    B13    B14  B15    B16  B17 
 
Figure-3. Serum protein profile of control (N3) and cases 
(B13-B17) in group I (70-79 yr.), resolved on 12% resolving 
gel by SDS-PAGE. 
M: Protein size markers (from top to bottom): 67, 45, 24, 
18, 13 and 1.45 kDa. 
 
 
 
   M    N4   B18   B19   B20   B21  B22   B23 
 
Figure-4. Serum protein profile of control (N4) and cases 
(B18-B23) in group I (> 80 yr.), resolved on 12% resolving 
gel by SDS-PAGE. 
M: Protein size markers (from top to bottom): 67, 45, 24, 
18, 13 and 1.45 kDa. 
 
DISCUSSIONS 
Benign prostate hyperplasia or benign prostatic 
hypertrophy (BPH) is an enlargement of prostate gland as 
man ages. Role of androgens seem to be prerequisites of 
BPH. Protein biomarkers are very useful for diagnosis and 
prognosis of various forms of cancers and other diseases. 
Certain proteins can be up or down regulated during 
disease progression. Detection of these differences in 
protein expression levels, as a function of disease 
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progression is important for prognosis. To distinguish 
between normal and pathological state of benign prostate 
hyperplasia, a qualitative analysis of Coomassie Brilliant 
Blue-stained proteins separated by SDS-PAGE was 
undertaken in this study. This procedure yielded 14 major 
protein fractions ranging in molecular weight from 1.45-
157 kDa, their appearance and raw volume in serum 
sample of each case was, studied (Figures, 1 to 4)  
On the whole, it was observed that raw volume of 
most protein fractions was increased in majority of BPH 
cases as compared to controls. In the present study protein 
fractions 55-57 kDa appeared in 56% of BPH cases (B4, 
B6, B7, B8, B10, B15, B16 and B18-B23) and was undetectable 
in normal controls under the age of 80 years. Similar 
findings were reported by other workers, who compared 
subcellular proteins of normal, BPH and prostate cancer 
cases using SDS-PAGE. They found significantly higher 
concentrations of non-histone proteins of 42 KD, 55KD 
and 190 KD in BPH cases than in the normal controls and 
cancer prostate, their results also showed that contents of 
other major protein species were similar in specimen of 
normal and diseased prostate cases [14]. Serum and not 
tissue samples were used in the present study to compare 
the protein profiles among study groups. Another study 
showed that 56 kDa protein fraction was up-regulated in 
86% of BPH cell lysate than prostate cancer and normal 
controls [15]. 
Previous studies have shown that the 
concentrations of most of the proteins are too little to be 
detected by Coomassie Blue staining. However, these 
proteins could not consider “unique” to their respective 
samples, because amount of proteins that did not exceed 
the minimum sensitivity of the dye may have been present 
in other samples [16]. In the present study, SDS-PAGE 
instead of 2D-PAGE and Coomassie Brilliant Blue R-250 
in place of silver staining was used; therefore, amount of 
protein fractions seen was much lesser. As quoted above, 
the protein fractions of 55-57 kDa, which were 
undetectable in the controls N1, N2 and N3 and was present 
in their corresponding BPH cases, cannot be considered 
totally absent in these controls as well as other BPH cases, 
because amounts of protein that did not exceed the 
minimum sensitivity of the dye could be present.  
In another study where serum proteins of prostate 
cancer were separated by SDS-PAGE, it was shown that 
protein fractions of molecular weights 1.27, 100, 114, 122, 
and 140 kDa were absent in significant number of prostate 
cancer cases [17]. In the present study also such an 
inconsistent behavior was shown by sample B2, B5 (Group 
I), B9, B12 (Group II) and B23 (Group IV), in that major 
protein fractions were either undetectable or down 
regulated in them. This might possibly due to some 
ailment other than prostate enlargement, since BPH cases 
were not necessarily clear of other health complications. 
Protein fractions of molecular weights 131, 122, 114 and 
100 kDa were absent in B5, B9, B12 (Group II) and B23 
(Group IV). Furthermore, 114kDa protein fraction was 
also found absent in B18 and B22 (Group IV). These results 
might be evident of their malignant transformation and 
need to be reassessed by other methods.   
CONCLUSIONS 
Further investigation of these samples could yield 
more information; silver staining, which is more sensitive 
than Coomassie Blue, would tell whether minute 
quantities of these protein fractions were present. Two 
dimensional gel electrophoresis would separate the 
proteins according to ionic potentials as well as molecular 
weight and thus achieve better resolution. Comparison of 
serum protein profiles in prostate cancer and benign 
prostatic hyperplasia along with normal controls can give 
an insight for the improvement
 in detection and diagnosis 
of BPH without any discrimination and unnecessary 
biopsies.  
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